ZS04 / Zensun - LARVOL DELTA

CASTLE-ZS-04: Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

An Ultrapotent Neutralizing Antibody Protected Non-Human Primates from Severe Fever with Thrombocytopenia Syndrome Virus Infection (IMMUNOLOGY 2025) - " Here, from SFTSV convalescent donors, we discovered an ultrapotent NAb ZS004-1C5 with subnanomolar neutralization titers (IC50=0.3 ng/mL)... Our findings provided proof-of-concept data to support clinical development of this antibody for SFTSV therapy, and discovered a novel neutralizing epitope that could benefit future vaccine design works.Keywords: Animals Non-Human Primate; Cells B Cells; Infections Viral; Molecules Antibodies; Tissues Spleen and Lymph Nodes"

Hematological Disorders • Infectious Disease • Inflammation • Thrombocytopenia • STAT1

Characterization of a ST137 multidrug-resistant Campylobacter jejuni strain with a tet(O)-positive genomic island from a bloodstream infection patient. (PubMed, Microb Pathog) - "LZCJ was resistant to norfloxacin, ampicillin, ceftriaxone, ciprofloxacin and tetracycline. This strain possessed a tet(O)-positive genomic island GI_LZCJ, which was closed to duck-derived C. jejuni ZS004, but with an additional ISChh1-like sequence. The above data indicated that the LZCJ strain may originate from foodborne bacteria on animals and the importance of continuous surveillance for the spread of foodborne bacteria."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology